Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin [April 2015]

Product Code:
596200349
Release Date:
April 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Multiple Sclerosis.  Topics covered: Momenta’s/Sandoz’s generic version of glatiramer acetate, Glatopa, advantages and disadvantages of Receptos’s ozanimod compared to Novartis’s Gilenya (fingolimod), MediciNova’s ibudilast, anti-LINGO-1 therapies, Mapi Pharma’s once-monthly glatiramer acetate depot formulation, Teva’s the three-times a week Copaxone formulation, Alkermes’ ALKS8700, Biogen’s Tecfidera (dimethyl fumarate).

Key Questions Answered in this Update Bulletin:

  • What do KOLs and payers think about Momenta’s/Sandoz’s generic version of glatiramer acetate, Glatopa, and how is this product likely to change treatment and reimbursement dynamics in the US when it’s launched in September 2015?
  • What do KOLs believe are the advantages and disadvantages of Receptos’s ozanimod compared to Novartis’s Gilenya (fingolimod), and where do KOLs see ozanimod being used in the MS treatment paradigm?
  • How aware are KOLs of MediciNova’s ibudilast, and what are their opinions of the drug as a potential treatment for progressive forms of MS?
  • What do KOLs think about the potential of anti-LINGO-1 therapies, particularly due to their novel mechanism of action?
  • How likely is it that the positive data for Biogen’s early stage optic neuritis study with BIIB 033 (an anti-LINGO-1 monoclonal antibody) will translate into efficacy in MS?
  • What are KOLs opinions of Mapi Pharma’s once-monthly glatiramer acetate depot formulation compared to more frequently dosed Copaxone formulations from Teva?
  • What impact will the approval of Teva’s the three-times a week Copaxone formulation have on current treatment practice, and how will the new Copaxone formulation fare against a generic glatiramer acetate product?
  • To what extent does Alkermes’ ALKS8700 have the potential to become a successful treatment for MS?
  • How much of an issue are the gastrointestinal effects that are common with Biogen’s Tecfidera (dimethyl fumarate)?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved